12:00 AM
Sep 13, 1999
 |  BC Week In Review  |  Company News  |  Deals

FibroGen, Taisho deal

The companies will develop human monoclonal antibodies against connective tissue growth factor (CTGF) and other factors to treat fibrotic kidney diseases. Taisho...

Read the full 99 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >